Global and Japan Recombinant Hepatitis B Vaccine Market Insights, Forecast to 2027

The hepatitis b vaccine is a vaccine against hepatitis b.That is, from hepatitis b virus carrier plasma isolation of hepatitis b surface antigen (HbsAg), after treatment and made.After second liver vaccine is inoculated, can stimulate immune system to produce protective antibody, this kind of antibody is in the humoral in the person, once second liver virus appears, antibody can act immediately, clear its, prevent infection, won't harm liver, make human body had the immunity that prevents second liver thereby.Therefore, hepatitis b vaccine has become an indispensable umbrella in life.Prevention generally lasts for at least 12 years, so there is no need for anti-hbs surveillance or enhanced immunity in the general population.However, anti-hbs surveillance can be carried out on high-risk groups, such as anti-hbs <10mIU/ml, which can be given enhanced immunity.

Market Analysis and Insights: Global and Japan Recombinant Hepatitis B Vaccine Market
This report focuses on global and Japan Recombinant Hepatitis B Vaccine market.
In 2020, the global Recombinant Hepatitis B Vaccine market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027. In Japan the Recombinant Hepatitis B Vaccine market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Recombinant Hepatitis B Vaccine Scope and Market Size
Recombinant Hepatitis B Vaccine market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Recombinant Hepatitis B Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For Japan market, this report focuses on the Recombinant Hepatitis B Vaccine market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in Japan.

Segment by Type
10mcg/ml
10mcg/0.5ml

Segment by Application
Newborn
Primary School Students
Adult

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Merck
GlaxoSmithKline Plc
Pfizer Inc.
Sanofi Pasteur
CSL Limited
Emergent Biosolutions
Serum Institute of India
Johnson & Johnson
Hualan Biological Engineering
NCPC
China National Biotec Group
Dalian Hissen Bio-pharm
Beijing Tiantan Biological